Vanguard Group
CDAK

Vanguard Group’s Codiak BioSciences, Inc. Common Stock CDAK Stock Holding History

Vanguard Group’s Portfolio CDAK Stock Details CDAK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-580,770
Closed -$101K – 4631
2023
Q1 		$101K Sell
580,770
-242,966
-29% -$135K ﹤0.01% 4403
2022
Q4 		$328K Buy
823,736
+379
+0% +$249 ﹤0.01% 4205
2022
Q3 		$644K Buy
823,357
+91,800
+13% +$193K ﹤0.01% 4150
2022
Q2 		$2.11M Buy
731,557
+115,989
+19% +$407K ﹤0.01% 3782
2022
Q1 		$3.86M Sell
615,568
-67,370
-10% -$423K ﹤0.01% 3650
2021
Q4 		$7.61M Buy
682,938
+20,080
+3% +$278K ﹤0.01% 3381
2021
Q3 		$10.8M Buy
662,858
+104,833
+19% +$1.88M ﹤0.01% 3197
2021
Q2 		$10.3M Buy
558,025
+147,614
+36% +$2.84M ﹤0.01% 3182
2021
Q1 		$6.19M Buy
410,411
+222,699
+119% +$4.84M ﹤0.01% 3415
2020
Q4 		$6.06M Buy
+187,712
New +$2.48M ﹤0.01% 3266

Vanguard Group's CDAK Position: Q2 2023 in Review

Vanguard Group sold out of Codiak BioSciences, Inc. Common Stock (CDAK) in Q2 2023, closing a stake of 580,770 shares — an estimated $101K sold.

Vanguard Group first reported a position in CDAK in Q4 2020 and held it in 10 quarters. The position peaked at $10.8M in Q3 2021. 1 fund tracked by Wall St. Rank holds CDAK as of Q2 2023.

  • Vanguard Group reported no remaining Codiak BioSciences, Inc. Common Stock position as of Q2 2023 after selling out during the quarter.
  • Vanguard Group sold 580,770 Codiak BioSciences, Inc. Common Stock shares in Q2 2023, an estimated $101K.
  • Vanguard Group first reported a position in Codiak BioSciences, Inc. Common Stock in Q4 2020 and held it in 10 quarters.
  • Vanguard Group's Codiak BioSciences, Inc. Common Stock position peaked at $10.8M in Q3 2021.
  • 1 fund tracked by Wall St. Rank held Codiak BioSciences, Inc. Common Stock as of Q2 2023.

Based on Vanguard Group's 13F filing for Q2 2023, filed 14 Aug 2023.